Canada Markets closed

Zomedica Pharmaceuticals Corp. (ZOM.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.28500.0000 (0.00%)
At close: 9:30AM EST
Full screen
Previous Close0.2850
Open0.2850
Bid0.1100 x 0
Ask0.4500 x 0
Day's Range0.2850 - 0.2850
52 Week Range0.2850 - 0.5200
Volume4,800
Avg. Volume0
Market Cap30.791M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Zomedica Announces Name Change

    ANN ARBOR, Mich., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic products for companion animals, announced that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will begin trading under the new name effective on October 5, 2020. The Company’s board of directors approved the implementation of the name change following approval from the shareholders at the Annual General and Special Virtual-Only Meeting of shareholders held on September 25, 2020.No action will be required by existing shareholders with respect to the name change. As a result of the name change, the Company’s common share CUSIP number is changed to 98980M109 and the ISIN is changed to CA98980M1095.Robert Cohen, Interim Chief Executive Officer stated, “Given Zomedica’s current focus on diagnostic products, and specifically the commercialization of TRUFORMA™, we believe it to be appropriate at this time to simplify our corporate name. We continue to make good progress on our strategic initiatives and remain excited about our upcoming commercialization plans.”About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.Follow Zomedica * Email Alerts: http://investors.zomedica.com * LinkedIn: https://www.linkedin.com/company/zomedica * Facebook: https://www.facebook.com/zomedica/ * Twitter: https://twitter.com/zomedicaInvestor Relations Contact: PCG Advisory Group Kirin Smith, COO ksmith@pcgadvisory.com +1 646.863.6519 www.pcgadvisory.com

  • GlobeNewswire

    Zomedica Announces Shareholder Meeting Voting Results

    ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”). At the Meeting, the Company’s shareholders approved the following proposals: * Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers, Rodney Williams, Chris MacLeod and Christopher Wolfenberg as directors; * Appointment of MNP LLP as the auditors of the Company and related matters; * Authorization of a reduction of the stated capital account applicable to the Common Shares of the Company in the discretion of the board of directors; * An amendment to the articles of the Company (the “Articles”) to remove a lien on a share registered in the name of a shareholder for a debt to the Company; * An amendment to the Articles allowing for shareholder meetings to be held outside of Alberta; * An amendment to the Articles to change the name of the Company from “Zomedica Pharmaceuticals Corp.” to “Zomedica Corp.”; and, * The ratification and confirmation of amendments to the Company’s by-laws. The proposal to effect a proposed share consolidation/reverse stock split of the Company’s common shares was approved by a majority of the shares voting at the Meeting but did not receive the required two-thirds majority vote required under Canadian law.Robert Cohen, Interim Chief Executive Officer of Zomedica, stated: “We believe that our core technology and planned products are strong, and that our future is bright. We remain focused on our key goal of advancing and bringing to market our lead product platform, TRUFORMA™, as expeditiously as possible. We have approximately US$50 million in cash and cash equivalents, and believe that our cash resources position us well beyond the TRUFORMA commercialization. We will update shareholders as we make additional progress with our key milestones. Additionally, we understand the value of listing on a major exchange and are exploring all options available. We clearly appreciate and hope to reward investors' patience in the not-too-distant future, as we believe that these are exciting times for our company.”Additional information regarding the voting on these matters will be filed separately by the Company on SEDAR (www.sedar.com) and EDGAR (www.sec.gov).The Company’s board of directors intends to effect the name change and amendments to the Articles to remove the lien on shares and to allow shareholder meetings to be held outside of Alberta. The ratification of the amendments to the by-laws requires no further action by the board of directors.The Company also is assessing its options with respect to effecting a reverse stock split of its common shares, which had been sought to maintain the continued listing of the common shares on the NYSE American.About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.Follow Zomedica * Email Alerts: http://investors.zomedica.com * LinkedIn: https://www.linkedin.com/company/zomedica * Facebook: https://www.facebook.com/zomedica/ * Twitter: https://twitter.com/zomedicaReader Advisory Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to Zomedica’s expectations regarding the public offering. Although we believe that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon Zomedica’s business operations generally, including Zomedica’s ability to develop its diagnostic products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.Investor Relations Contact: PCG Advisory Group Kirin Smith, COO ksmith@pcgadvisory.com +1 646.863.6519

  • GlobeNewswire

    Zomedica Announces Letter to Shareholders in Connection With Annual and Special Virtual-Only Meeting

    ANN ARBOR, Mich., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that its proxy solicitor, Alliance Advisors, mailed the following letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders to be held on September 25, 2020.  Dear Zomedica Pharmaceuticals Corp. Shareholder:Our records reflect that you have not yet voted your shares with respect to Proposal 3 to be acted upon at the Annual and Special Virtual-Only Meeting of Zomedica Pharmaceuticals Corp. to be held on Friday, September 25, 2020 at 8:30 a.m., Eastern time, pursuant to which shareholders are being asked to approve a reverse stock split, or consolidation, of our common shares at a ratio between one-for-25 and one-for-50.The reverse stock split is intended to increase the per share trading price of our common shares in order to maintain the listing of the common shares on the NYSE American exchange. The board believes that it is in the best interest of shareholders to effect a reverse split to maintain our NYSE American listing. Additionally, increasing the trading price of our common shares could increase the interest of institutional and other investors in our common shares and may expand the pool of investors that may consider investing in our company. If we are unable to maintain our NYSE American listing, our common shares would cease to trade on the NYSE American and would trade in the over-the-counter market on either the OTC Bulletin Board or the “pink sheets” maintained by the National Quotation Bureau. We believe the loss of our NYSE American listing would significantly impact the liquidity of your common shares and could negatively affect the trading price of your common shares. As a result, the board recommends that you vote your shares FOR Proposal 3.Please note that the reverse stock split will affect all of our shareholders uniformly and will not affect any shareholder’s percentage ownership interest or proportionate voting power, except for minor adjustment due to fractional shares.Please vote your shares today by calling (833) 670 – 0700 Monday through Friday, 9:00 a.m. to 10:00 p.m. Eastern Time.Alternatively, if you wish you can email me your voting instructions at mcarlson@allianceadvisors.com.Sincerely, Melissa CarlsonVice PresidentAbout ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.Follow Zomedica * Email Alerts: http://investors.zomedica.com * LinkedIn: https://www.linkedin.com/company/zomedicaAdditional Information Zomedica Pharmaceuticals Corp. has prepared a Management Proxy Circular and Proxy Statement dated August 6, 2020, as well as a supplement thereto dated August 20, 2020 (collectively, the “Circular”). The Circular is being provided to shareholders pursuant to notice and access procedures under applicable securities laws that we are utilizing in connection with the meeting, and also may be accessed at the Company’s profile on EDGAR in the United States at www.sec.gov and on SEDAR in Canada at www.SEDAR.com. Further, copies of the Circular may be obtained from our proxy solicitor, Alliance Advisors at pcasey@allianceadvisors.com. Shareholders are strongly advised to read the Circular and related meeting materials before voting on matters to be considered at the meeting.Investor Relations & Media Contact: PCG Advisory Group Kirin Smith, COO ksmith@pcgadvisory.com +1 646.863.6519 www.pcgadvisory.com